Page last updated: 2024-10-18

dalteparin and Low Bone Density

dalteparin has been researched along with Low Bone Density in 3 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

ExcerptRelevanceReference
"We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD."9.12Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007)
"We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD."5.12Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007)
" An initial dosage of 1."1.34Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007)
"In contrast, LMWH, causes less osteopenia than heparin because it only decreases the rate of bone formation."1.30A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. ( Andrew, M; Hirsh, J; Muir, JM; Shaughnessy, SG; Weitz, JI; Young, E, 1997)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Malowany, JI1
Knoppert, DC1
Chan, AK1
Pepelassis, D1
Lee, DS1
Rodger, MA1
Kahn, SR1
Cranney, A1
Hodsman, A1
Kovacs, MJ1
Clement, AM1
Lazo-Langner, A1
Hague, WM1
Muir, JM1
Hirsh, J1
Weitz, JI1
Andrew, M1
Young, E1
Shaughnessy, SG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721]40 participants (Anticipated)Interventional2008-03-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for dalteparin and Low Bone Density

ArticleYear
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:8

    Topics: Adult; Anticoagulants; Bone Density; Bone Diseases, Metabolic; Dalteparin; Female; Humans; Middle Ag

2007

Other Studies

2 other studies available for dalteparin and Low Bone Density

ArticleYear
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Pharmacotherapy, 2007, Volume: 27, Issue:9

    Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E

2007
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.
    Blood, 1997, May-01, Volume: 89, Issue:9

    Topics: Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Bone and Bones; Bone Development; Bone Disea

1997